Vic J. Verwaal
维克·费尔瓦尔
MD, PhD
Surgical Oncologist外科肿瘤学家
👥Biography 个人简介
Vic Verwaal conducted the first randomized controlled trial demonstrating survival benefit of CRS + HIPEC over systemic chemotherapy for colorectal peritoneal metastases, published in the Journal of Clinical Oncology in 2003. This Dutch RCT became the cornerstone evidence establishing HIPEC as a standard treatment option and prompted global adoption of the combined approach.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
First RCT of HIPEC for Colorectal Peritoneal Metastases
Led the landmark Dutch randomized trial comparing CRS + HIPEC versus standard systemic chemotherapy in colorectal peritoneal carcinomatosis, demonstrating significant improvement in median survival (22.3 vs 12.6 months), the pivotal evidence establishing HIPEC as standard of care.
8-Year Follow-up Outcomes
Published 8-year follow-up data from the Dutch RCT, confirming sustained long-term survival benefit with CRS + HIPEC and 45% cure rate in patients achieving complete cytoreduction, validating the curative potential of the approach.
Patient Selection and Surgical Outcomes
Defined key prognostic factors and patient selection criteria for optimal CRS + HIPEC outcomes, informing international guidelines on treatment eligibility and surgical technique.
Representative Works 代表性著作
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
Journal of Clinical Oncology (2003)
Landmark RCT demonstrating survival superiority of CRS + HIPEC over palliative chemotherapy in colorectal peritoneal metastases; foundational evidence for HIPEC adoption.
Survival of patients with peritoneal carcinomatosis from colorectal cancer treated by cytoreduction and hyperthermic intraperitoneal chemotherapy
European Journal of Surgical Oncology (2007)
Long-term follow-up confirming durable survival benefit and curative potential of CRS + HIPEC, with prognostic analysis by completeness of cytoreduction.
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer
Annals of Surgical Oncology (2008)
Extended follow-up data solidifying the long-term benefit and cure rate achievable with optimal cytoreduction.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 维克·费尔瓦尔 的研究动态
Follow Vic J. Verwaal's research updates
留下邮箱，当我们发布与 Vic J. Verwaal（Netherlands Cancer Institute – Antoni van Leeuwenhoek）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment